IOVS Physiological Reviews
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lambooij, A. C.
Right arrow Articles by Mooy, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lambooij, A. C.
Right arrow Articles by Mooy, C. M.
(Investigative Ophthalmology and Visual Science. 2000;41:2329-2335.)
© 2000 by The Association for Research in Vision and Ophthalmology, Inc.

Somatostatin Receptor 2A Expression in Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Antoinette C. Lambooij1, Robert W. A. M. Kuijpers1, Elgin G. R. van Lichtenauer–Kaligis2, Mike Kliffen3, G. Seerp Baarsma4, P. Martin van Hagen2 and Cornelia M. Mooy1,3,5

From the Departments of 1 Ophthalmology, 2 Immunology and Internal Medicine III, and 3 Pathology, Erasmus University Rotterdam; 4 The Eye Hospital, Rotterdam; and the 5 Pathology Laboratory, Dordrecht, The Netherlands.

PURPOSE. The growth of ocular neovascularization is regulated by a balance between stimulating and inhibiting growth factors. Somatostatin affects angiogenesis by inhibiting the growth hormone–insulin-like growth factor axis and also has a direct antiproliferative effect on human retinal endothelial cells. The purpose of our study is to investigate the expression of somatostatin receptor (sst) subtypes and particularly sst subtype 2A (sst2A) in normal human macula, and to study sst2A in different stages of age-related maculopathy (ARM), because of the potential anti-angiogenic effect of somatostatin analogues.

METHODS. Sixteen eyes (10 enucleated eyes, 4 donor eyes, and 2 surgically removed choroidal neovascular [CNV] membranes) of 15 patients with eyes at different stages of ARM were used for immunohistochemistry. Formaldehyde-fixed paraffin-embedded slides were incubated with a polyclonal anti-human sst2A antibody. mRNA expression of five ssts and somatostatin was determined in the posterior pole of three normal human eyes by reverse transcriptase–polymerase chain reaction.

RESULTS. The immunohistochemical expression of sst2A in newly formed endothelial cells and fibroblast-like cells was strong in fibrovascular CNV membranes. mRNA of sst subtypes 1, 2A, and 3, as well as somatostatin, was present in the normal posterior pole; sst subtypes 4 and 5 were not detectable.

CONCLUSIONS. Most early-formed CNV in ARM express sst2A. The presence of mRNA of sst subtype 2A was observed in normal human macula, and subtypes 1 and 3 and somatostatin are also present. sst2A receptors bind potential anti-angiogenic somatostatin analogues such as octreotide. Therefore, somatostatin analogues may be an effective therapy in early stages of CNV in ARM.




This article has been cited by other articles:


Home page
 IOVSHome page
S. S. Palii, A. Afzal, L. C. Shaw, H. Pan, S. Caballero, R. C. Miller, S. Jurczyk, J.-C. Reubi, Y. Tan, G. Hochhaus, et al.
Nonpeptide Somatostatin Receptor Agonists Specifically Target Ocular Neovascularization via the Somatostatin Type 2 Receptor
Invest. Ophthalmol. Vis. Sci., November 1, 2008; 49(11): 5094 - 5102.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
C. Hernandez, E. Carrasco, R. Casamitjana, R. Deulofeu, J. Garcia-Arumi, and R. Simo
Somatostatin Molecular Variants in the Vitreous Fluid: A comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects
Diabetes Care, August 1, 2005; 28(8): 1941 - 1947.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
A. Vasilaki, T. Papadaki, G. Notas, G. Kolios, N. Mastrodimou, D. Hoyer, M. Tsilimbaris, E. Kouroumalis, I. Pallikaris, and K. Thermos
Effect of Somatostatin on Nitric Oxide Production in Human Retinal Pigment Epithelium Cell Cultures
Invest. Ophthalmol. Vis. Sci., May 1, 2004; 45(5): 1499 - 1506.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
A. C. Lambooij, K. H. M. van Wely, D. J. Lindenbergh-Kortleve, R. W. A. M. Kuijpers, M. Kliffen, and C. M. Mooy
Insulin-like Growth Factor-I and its Receptor in Neovascular Age-Related Macular Degeneration
Invest. Ophthalmol. Vis. Sci., May 1, 2003; 44(5): 2192 - 2198.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
R. Simo, A. Lecube, L. Sararols, J. Garcia-Arumi, R. M. Segura, R. Casamitjana, and C. Hernandez
Deficit of Somatostatin-Like Immunoreactivity in the Vitreous Fluid of Diabetic Patients: Possible role in the development of proliferative diabetic retinopathy
Diabetes Care, December 1, 2002; 25(12): 2282 - 2286.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
D. D. Klisovic, M. S. O'Dorisio, S. E. Katz, J. W. Sall, D. Balster, T. M. O'Dorisio, E. Craig, and M. Lubow
Somatostatin Receptor Gene Expression in Human Ocular Tissues: RT-PCR and Immunohistochemical Study
Invest. Ophthalmol. Vis. Sci., September 1, 2001; 42(10): 2193 - 2201.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the Association for Research in Vision and Ophthalmology